Lupus nephritis: An historical perspective 1968-1998

Journal of Nephrology

Volumn 12, Issue SUPPL. 2, 1999, Pages

  Cameron, J Stewart ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Elmbank   (United Kingdom)

Author keywords

Anti DNA antibodies; Autoimmunity; History of medicine; Immunosuppressive drugs; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY;

HUMAN; IMMUNOLOGY; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; PATHOLOGY; REVIEW; SURVIVAL RATE;

AUTOANTIBODIES; HUMANS; KIDNEY; LUPUS NEPHRITIS; SURVIVAL RATE;

EID: 0001798250     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
2. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osier. Rheum Clin N Am 1988; 14: 1-14.
3. Virchow R. Historische Notizen über Lupus. Arch Pathol Anat 1865; 32: 139-43.
4. TalbottJH. Historical background of discoid and systemic lupus erythematosus. In: Wallace DJ Hahn BH, eds. Dnbois' lupus erythematosus. Lea and Febiger, Philadelphia 1993; 3-10.
5. Evans PR. The early history of the wolf. J Roy Coll Physcns Lond 1988; 22: 139.
6. Rowell NR. Some historical aspects of skin disease in lupus erythematosus. Lupus 1997; 6: 76-83.
7. Potter B. The history of the disease called lupus. J Hist Med 1993; 20:1760-3.
8. Hochberg MC. The history of lupus erythematosus. Maryland MedJ 1991; 40: 871-3.
9. Kaposi M. Neue Berichte Über die Kentniss der Lupus Erythematosus. Arch Derm Syph 1872; 4: 36-8. see also: Hebra F, Kaposi M. On diseases of the skin, including the exanthemata, (tr. WTay. Ed. Hilton Fagge C). The New Sydenham Society, London, 1886-1890; 1874.
10. Brooke HG. Lupus erythematosus and tuberculosis. BrJ Dermatol 1895; 7: 73-7.
11. Jadassohn J. Handbuch der Hautkrankheiten. F Mraech, Berlin 1904; 3: 298424.
12. Osier W. On the visceral manifestations of the erythema group of skin diseases. AmJ Med Sei 1904; 127: 1-23.
13. Benedek TG. William Osier and development of the concept of systemic lupus erythematosus. Sem Arth Rheum 1997; 27: 48-56.
14. Keith NM, Rowntree LG. Study of renal complications of disseminated lupus erythematosus: report of four cases. Trans Assoc Am Physns 1922; 37: 487-502.
15. Baehr G, Klemperer P, Schifrin A. Diffuse disease of the peripheral circulation usually associated with lupus erythematosus and endocarditis. Trans Assoc Am Physns 1935; 50: 139-55.
16. Klemperer P, Pollack AD, Baehr G. Pathology and disseminated lupus erythematosus. Arch Pathol 1941; 32: 569-631.
17. Lister LM, Baker RD. Needle biopsy of the kidney in die diagnosis of disseminated lupus erythematosus. Am J Med 1954; 17: 851-5.
18. Muehrcke RC, Kark RM, Pirani CL, Pollak VE. Lupus nephri-tis: a clinical and pathological study based on renal biopsies. Medicine (Baltimore) 1957; 36: 1-146.
19. Farquar MG, Vernier RL, Good RA. An electron microscope study of the glomerulus in nephrosis, glpmerulonephritis and lupus erythematosus. J Exp Med 1957; 106: 649-60.
20. Mellors RC, Ortega LG, Holman HR. Role of gamma globulins in pathogenesis of renal lesions in systemic lupus erythematosus and chronic membranous glomerulonephritis, with observations on the lupus erythematosus cell reaction. J Exp Med 1957; 106: 191-201.
21. Freedman P, Peters JH, Kark RM. Localization of gamma globulin in the diseased kidney. Arch Intern Med 1960; 105: 524-35.
22. PetersJH, Freedman P. Immunologie aspects of renal disease. N EnglJ Med 1959; 261: 1166-73, 1225-35, 1275-81 (three parts).
23. Gennerich W. Der gegenw'rtig Zustande zur Frage Lupus Erythematosus. Arch Derm Syph 1922; 138: 403-10.
24. Hargreaves MM, Richmond H, Morton R. Presentation of 2 bone marrow elements; the "tart" cell and the "LE" cell. Proc Staff Meet Mayo Clinic 1948; 23: 25-8.
25. Hargreaves MM. Discovery of the LE cell and its morphology. Mayo Clin Proc 1969; 94: 56-69.
26. Miescher P, Fauconnet L. L'absorption du facteur LE par les noyaux cellulaires isotes. Experientia 1954; 10: 252.
27. Friou GJ. The significance of the lupus globulin-nucleoprotein reaction. Ann Intern Med 1958; 49: 866-74.
28. Friou GJ. Setting the scene: a historical and personal view of immunologie diseases. Clin Exp Rheumatol 1994; 12 (suppl ll):S23-5.
29. Holborow FJ, Weir DM, Johnson GD. A serum factor in lupus erythematosis with affinity for tissue nuclei. Br MedJ 1957; ii: 732-1.
30. Seligmann M. Demonstration in the blood of patients with disseminated lupus erythematosus a substance determining a precipitation reaction with desoxyribonucleic acid. C Rend Acad Sei (Paris) 1957; 244: 243-5.
31. Bielschowsky M, Helyer BJ, HowieJB. Spontaneous haemolytic anaemia in mice of the NZB/B1 strain. Proc Univ Otago Med School (NZ) 1959; 37: 9-11.
32. Thorn GW, Forsham PH, Frawley TF, Hill SRJr, Smith S, Warren DL. Medical progress: the clinical usefulness of ACTH and cortisone. N EnglJ Med 1950; 242: 824-34.
33. ElkingtonJR, Hunt AD Jr, Godrey L, McCrory WW, Rogerson, AG, Stokes J Effects of pituitary adrenocorticotrophic hormone (ACTH) therapy.JAMA 1949; 141: 1273-9.
34. Dubois EL, Commons RR, Starr P, Stein CS Jr, Morrison R. Corticotrophin and cortisone treatment for systemic lupus erythematosus.JAMA 1952; 149: 995-1002.
35. Grace AW, Combes FC. Remission of disseminated lupus erythematosus induced by adrenocorticotrophin. Proc Soc Exp Biol Med 1949; 72: 563-5.
36. Chasis H, Goldring W, Baldwin DS. Effect of febrile plasma typhoid laccine and nitrogen mustard on renal manifestations of human glomerulonephritis. Proc Soc Exp Biol Med 1949; 71:565-7.
37. Robn RJ, Bond WH. Some effects of nitrogen mustard and trimcthylene melamine in acute disseminated lupus erythematosus. AmJ Med Sei 1950; 226: 179-90.
38. Kellum RE, HaserickMechlorelhainine therapy for systemic lupus nephropathy. Analysis and review often years' experience and a clinical study of 211 cases including 81 padents treated with mechlorethamine. Arch Dermatol 1963; 87: 289-98.
39. Dubois EL. Lupus erythematosus. University of Southern California Press, Los Angeles, 1966.
40. Burnet FM. The clonal theory of acquired immunity. Cambridge University Press, 1959.
41. Gell PGH, Coombs RRA. Clinical aspects of immunology. Blackwell, Oxford, 1963.
42. Dixon FJ. What are sensitised cells doing in glomerulonephritis ? N EnglJ Med 1970; 283:536 -7.
43. Koffler D, Agenello V, Thoburn R, Kunkel HG. Systemic lupus erythematosus: prototype of immune complex nephritis in man.J Exp Med 1971; 134; 169s-79s.
44. Dixon FJ, Feldman JD, Vasquez J. Experimental glomerulonepritis. The pathogenesis of a laboratory model resembling the spectrum of human nephritis. J Exp Med 1961; 113: 899-920.
45. Dixon FJ. The pathogenesis of glomerulonephritis. AmJ Med 1968; 44: 493-8.
46. Germuth F, Rodriguez E. The immunopathology of the renal glomerulus. Little Brown, Boston. 1973.
47. Agnello V, Kofller D, Eisenberg JW, Winchester RJ, Kunkel HJ. Clq precipitins in the sera of patient with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 1971; 134: 228-41.
48. Lachman PJ, Muller-Eberhard HJ, Kunkel HG, Paronetto F. The localisation of in vivo bound complement in tissue sections. J Exp Med 1962; 115: 63-82.
49. Freedman P, Markowitz AS. Gamma globulin and complement in the diseased kidney. J Clin Invest 1962; 41: 328-34.
50. Paronetto F, Koffler D. Immunofluorescent localisation of immunoglobulins, complement and fibrinogen in human disease. I Systemic lupus erythematosus. J Clin Invest 1965; 44: 1657-64.
51. Krishnan C, Kaplan MH. Immunopathologic studies of systemic lupus erythematosus. II anti-nuclear reaction of gamma globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis. J Clin Invest 1967; 46: 569-79.
52. Koffler D, Shur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967; 126: 607-23.
53. Cochrane CG. Mediation of immunologie glomerular injury. Transpl Proc 1969; 1: 949-58.
54. Lange K, Wasserman E, Slobody LB. The significance of serum complement levels for the diagnosis and prognosis of acute and subacute glomeruloncphritis and lupus erythe-matosus. Ann Intern Med I960; 53: 636-46.
55. Shigematsu H, Shishido H, Kuhara K, Tsuchida H, Suzuki H, Hirose K, Tqjo S. Participation of monocytes in the transient hypercellularity in post-streptococcal nephritis. Virchows Archiv B 1973; 12: 367-70.
56. Vassal! P, McCluskey RT. The pathogenic role of the coagulation process in rabbit Masugi nephritis. AmJ Pathol 1964; 45: 653-77.
57. Kincaid-Smith P, Sacker UM, Fairley KF. Anticoagulants in "irreversible" renal failure. Lancet 1968; ii: 1360-3.
58. Dtimonde DC. "Lymphokines". Mediators and regulators of cellular immune responses. Ann Immunol 1970; II: 129-42.
59. Kellum RE, HaserickSystemic lupus erythematosus. A statistical evaluation of mortality based on a consecutive series of 299 patients. Arch Intern Med 1963; 113: 200-7.
60. Pirani CL, Pollak VE, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63: 537-50.
61. Baldwin DS, Lowenstein J; Rothfield NF, Gallo G, McCluskey RT. The clinical course of proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970; 73: 929-42.
62. Estes D. Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971;50:85-95.
63. Report to the Medical Research Council by the collagen diseases and hypersensitivity panel. Treatment of systemic lupus erythematosus with steroids. BrMedJ 1961; ii: 915-20.
64. Cohen AS, Reynolds WE, Franklin EC, KulkaJP, Ropes MW, Shulman LE, Wallace SL. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971; 21:643-8.
65. Hughes GRV, Cohen SA, Christian C. Anti-DNA activity in SLE. A diagnostic and therapeutic guide. Ann Rheum Dis 1971; 30: 259-64.
66. Comerford FR, Cohen AS. The nephropathy of systemic lupus erythematosus. An assessment by clinical, light and electron microscopic criteria. Medicine (Baltimore) 1967; 46: 425-73.
67. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions of and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961; 57: 495-511.
68. Hill RD, Scott GW. Cytotoxic drugs for systemic lupus. Br Med J 1964; i: 370 (letter).
69. Seah CS, Wong KH, Chew AGK, Jayaratnam FJ. Cyclophosphamide in the treatment of systemic lupus erythematosus. Br MedJ 1966; i: 33-5.
70. Cameron JS, Boulton Jones M, Robinson R, Ogg C. Treatment of lupus nephritis with cyclophosphamide. Lancet 1970; ii: 846-8.
71. Lorenzen I, Vidbaek Aa. Treatment of collagen diseases with cytostatics. Lancet 1965; ii: 558-61.
72. Corley CC, Lessner HE, Larsen WE. Azathioprine therapy of "autoimmune" diseases. AmJ Med 1966; 41: 404-12.
73. Cruchaud A, Pometta D, Rousso C. Treatment of lupus erythematosus (SLE) with immunosuppressive drugs. An analysis of the immunologie data. Helv Med Acta 1967; 34:5-22.
74. Drinkard JP, Stanley TM, Dornfeld L, Austin RC, Barnett EV, Pearson CM, Vernier RL, Adams DA, Latta H, Gonick HC. Azathioprine in the treatment of adults with lupus nephritis. Clinical, histological and immunologie changes with therapy. Medicine (Baltimore) 1970; 49: 411-32.
75. Mäher JF, Schreiner GE. Treatment of lupus nephritis with azathioprine. Ann Intern Med 1970; 125: 293-8.
76. CameronJS. Systemic lupus erythematosus. In: Nielson EG, Couser WG eds. Immunologie renal disease. Philadelphia: Lippincott-Raven, 1997; 1055-94.
77. Wallace DH, Hahn BH, eds. Dubois' lupus erythematosus 4th ed. Baltimore, Lea & Febiger, 1993.
78. Lewis EJ, Korbet S, Schwarte M (eds). Lupus nephritis. Oxford University Press, London, 1999.
79. Walport MJ. The pathogenesis of systemic lupus erythematosus. In: Davison AM, Cameron JS, Grünfeld J-P, Kerr DNS, Ritz E, Winearls CG, eds. Oxford textbook of clinical nephrology 2nd Ed. London, Oxford University Press; 1997: 917-35.
80. Hahn BH. Antibodies to DNA. N EnglJ Med 1998; 338:1359-68.
81. Casciola-Rosen L, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-30.
82. Berden JHM. Lupus nephritis (nephrology forum) Kidney Int 1997; 52: 538-58.
83. Alexopoulos E, CameronJS, Hartley BH. Lupus Nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37: 100-9.
84. Asherson RA, Cervera R, Piette J-C, Schoenfeld Y. The antiphospholipid syndrome. Boca Raton, CRC Press, 1996.
85. 84a.Kobayashi T, Stang E, Fang KS, de Moerloose P, Parton RG, GruenbergJ. A lipid associated with the antiphospholipid syndrome regulates endosomal structure and function. Nature 1998; 392: 193-7.
86. Kashgarian M. Lupus nephritis: lessons from the path lab. Kidney Int 1994; 45:928-38.
87. ChurgJ, Bernstein J, Glassock RJ. Renal Disease. Tokyo, Ikagu-Shoin 1995; 151-79.
88. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499-515.
89. Bono L, CameronJS, HicksJ. The very long term course of lupus nephritis. QJ Med 1999; 92: 211-8.
90. Ropes MW. Observations on the natural history of disseminated lupus erythematosus. Medicine (Baltimore) 1964; 43: 387-91.
91. Nossent HC, SwaakTJG, Berden JHM and the Dutch working party on systemic lupus erythematosus. Analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. AmJ Med 1990; 89: 169-74.
92. Nossent HC, SwaakTJG, Berden JHM and the Dutch working party on SLE. Systemic lupus erythematosus after renal transplantation: patients and graft survival and disease activity. Ann Intern Med 1981; 114: 183-8.
93. Lochhead KM, Pirsch JD, D'Alessandro AM, Knechtle SJ, Kalayoglu M, Sollinger HW, Beizer FO. Risk factors for allograft loss in patients with systemic lupus erythematosus. Kidney Int 1996; 49:512-7.
94. Ward LA, Jelveh Z, Feinfeld DA. Recurrent membranous lupus nephritis after renal transplantation: a case report and review of the literature. AmJ Kidney Dis 1994; 23: 326-9.
95. Donadio JV, Hart GM, Bergstralh EJ Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 09-115.
96. DonadioJV, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. AmJ Kidney Dis 1993; 21: 239-50.
97. CameronJS. What is the role of long-term cytotoxic agents in the treatment of lupus nephritis ?J Nephrol 1993; 6: 172-6.
98. Felson DT, Anderson J. Evidence for the superiority of im-munosuppressive drugs and prcclnisone over prcdnisone alone in lupus nephritis. N EnglJ Med 1984; 311: 1528-33.
99. Bansal VK, Beto JA. Treatment of lupus nephritis: a metaanalysis of clinical trials. AmJ Kidney Dis 1997; 29: 193-9.
100. Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM, for the lupus nephritis collaborative study group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N EnglJ Med 1992; 326: 1373-9.
101. Euler HH, Schwab UM, Schroeder JO, HasfordJ. The lupus plasmapheresis study group: rationale and updated report. Artif Organs 1996; 20: 356-9.
102. BalowJE, Austin HA, Muenz LR, Joyce KM, Antonyovich TT, KlippelJH, Steinberg AD, Plotz PH, Decker JL. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N EnglJ Med 1984; 311: 491-5.
103. Austin HA III, KlippelJH, BalowJE, Le Riche NGH, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of preduisone and cytotoxic drugs. N EnglJ Med 1986; 314: 614-9.
104. Steinberg AD, Stcinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamiile versus those treated with prednisolone alone. Arthritis Rheum 1991; 34: 945-50.
105. Boumpas DT, Austin HA III, Vaughan EM, KlippelJH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimes of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5.
106. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, KlippelJH, BalowJE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9.
107. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 27-34.
108. Ginzler'"E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 37-44.
109. Ponticelli C. Treatment of lupus nephritis- the advantages of a flexible approach. Nephrol Dial Transplant 1997; 12: 2057-9.
110. Lin C-Y, Hsu H-C, Chiang H. Improvement in histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989;
111. Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995; 5: 1745-50.
112. KaldenExperimental approaches to the treatment of systemic lupus erythematosus. Sem Clin Immimol 1996; 12: 25-30. © Société Italiana di Nefrologia